Muscular Dystrophy

References

Anderson JL, Head SI, et al. Brain function in Duchenne muscular dystrophy. Brain. 2002;125:4–13.

Aparicio LF, Jurkovic M, et al. Decreased bone density in ambulatory patients with duchenne muscular dystrophy. J Pediatr Orthop. 2002;22:179–81.

Archer JD, Vargas CC, et al. Persistent and improved functional gain in mdx dystrophic mice after treatment with L-arginine and deflazacort. FASEB J. 2006 Apr;20(6):738–40.

Balaban B, Matthews DJ. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: Long-term effect. Am J Phys Med Rehabil. 2005 Nov;84(11):843–50.

Balagopal P, Olney R, et al. Oxandrolone enhances skeletal muscle myosin synthesis and alters global gene expression profile in Duchenne muscular dystrophy. Am J Physiol Endocrinol Metab. 2006 Mar;290(3):E530–E539.

Barton ER, Morris L, et al. Systemic administration of L-arginine benefits mdx skeletal muscle function. Muscle Nerve. 2005 Dec;32(6):751–60.

Beenakker EA, Fock JM, et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: A randomized controlled trial. Arch Neurol. 2005 Jan;62(1):128–32.

Bianchi ML, Mazzanti A, et al. Bone mineral density and bone metabolism in Duchenne muscular dystrophy. Osteoporos Int. 2003 Sep;14(9):761–7.

Billard C, Gillet P, et al. Reading ability and processing in Duchenne muscular dystrophy and spinal muscular atrophy. Dev Med Child Neural. 1998;40:12–20.

Buetler TM, Renard M, et al. Green tea extract decreases muscle necrosis in mdx mice and protects against reactive oxygen species. Am J Clin Nutr. 2002 Apr;75(4):749–53.

Chaubourt E, Fossier P, et al. Nitric oxide and 1-arginine cause an accumulation of utrophin at the sarcolemma: A possible compensation for dystrophin loss in Duchenne muscular dystrophy. Neurobiol Dis. 1999 Dec;6(6):499–507.

Chaubourt E, Voisin V, et al. Muscular nitric oxide synthase (muNOS) and utrophin. J Physiol Paris. 2002 Jan-Mar;96(1-2):43–52.

Conte Camerino D, Tricarico D, et al. Taurine and skeletal muscle disorders. Neurochem Res. 2004 Jan;29(1):135–42.

Cooper R, Morre DJ, et al. Medicinal benefits of green tea: Part I. Review of noncancer health benefits. J Altern Complement Med. 2005 Jun;11(3):521–8.

De Luca A, Pierno S, et al. Alteration of excitation-contraction coupling mechanism in extensor digitorum longus muscle fibres of dystrophic mdx mouse and potential efficacy of taurine. Br J Pharmacol. 2001 Mar;132(5):1047–54.

De Luca A, Pierno S, et al. Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. J Pharmacol Exp Ther. 2003 Jan;304(1):453–63.

Dorchies OM, Wagner S, et al. Green tea extract and its major polyphenol (-)-epigallocatechin gallate improve muscle function in a mouse model for Duchenne muscular dystrophy. Am J Physiol Cell Physiol. 2006 Feb;290(2):C616–C625.

Dubowitz V. Muscle disorders in childhood. 2nd ed. London: WB Saunders Company Ltd; 1995.

Escolar DM, Buyse G, et al. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. Ann Neurol. 2005 Jul;58(1):151–5.

Felber S, Skladal D, et al. Oral creatine supplementation in Duchenne muscular dystrophy: A clinical and 31P magnetic resonance spectroscopy study. Neurol Res. 2000 Mar;22(2):145–50.

Ferrucci L, Cherubini A, et al. Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. J Clin Endocrinol Metab. 2006 Feb;91(2):439–46.

Folkers K, Simonsen R. Two successful double blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenie atrophies. Biochim Biophys Acta. 1995;1271:281–6.

Griggs RC, Pandya S, et al. Randomized controlled trial of testosterone in myotonic dystrophy. Neurology. 1989 Feb;39(2 Pt 1):219–22.

Guglieri M, Magri F, et al. Molecular etiopathogenesis of limb girdle muscular and congenital muscular dystrophies: Boundaries and contiguities. Clin Chim Acta. 2005 Nov;361(1-2):54–79.

Hankard RG, Hammond D, et al. Oral glutamine slows down whole body protein breakdown in Duchenne muscular dystrophy. Pediatr Res. 1998 Feb;43(2):222–6.

Hankard R, Mauras N, et al. Is glutamine a ‘conditionally essential’ amino acid in Duchenne muscular dystrophy? Clin Nutr. 1999 Dec;18(6):365–9.

Kasai T, Abeyama K, et al. Decreased total nitric oxide production in patients with duchenne muscular dystrophy. J Biomed Sci. 2004 Jul-Aug;11(4):534–7.

Katiyar SK. Skin photoprotection by green tea: Antioxidant and immunomodulatory effects. Curr Drug Targets Immune Endocr Metabol Disord. 2003 Sep;3(3):234–42.

Katiyar SK, Elmets CA. Green tea polyphenolic antioxidants and skin photoprotection (Review). Int J Oncol. 2001 Jun;18(6):1307–13.

La Guardia M, Giammanco S, et al. Omega 3 fatty acids: Biological activity and effects on human health. Panminerva Med. 2005 Dec;47(4):245–57.

Larson CM, Henderson RC. Bone mineral density and fractures in boys with Duchenne muscular dystrophy. J Pediatr Orthop. 2000;20:711–4.

Leighton S. Nutrition for boys with Duchenne muscular dystrophy. (Review). Nutrition & Dietetics: J Dieticians Asso of Australia. 2003 March;60(1):11–6.

Levis S, Gomez A, et al. Vitamin D deficiency and seasonal variation in an adult South Florida population. J Clin Endocrinol Metab. 2005 Mar;90(3):1557–62.

Louis M, Lebacq J, et al. Beneficial effects of creatine supplementation in dystrophic patients. Muscle Nerve. 2003 May;27(5):604–10.

Manzur AY, Kuntzer T, et al. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2004;(2):CD003725.

Marques MJ, Luz MA, et al. Muscle regeneration in dystrophic mdx mice is enhanced by isosorbide dinitrate. Neurosci Lett. 2005 Jul 15;382(3):342–5.

Morley N, Clifford T, et al. The green tea polyphenol (-)-epigallocatechin gallate and green tea can protect human cellular DNA from ultraviolet and visible radiation-induced damage. Photodermatol Photoimmunol Photomed. 2005 Feb;21(1):15–22.

Nieto-Ceron S, del Campo LF, et al. Muscular dystrophy by merosin deficiency decreases acetylcholinesterase activity in thymus of Lama2dy mice. J Neurochem. 2005 Nov;95(4):1035–46.

Orr R, Fiatarone Singh M. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: Review of efficacy and safety. Drugs. 2004;64(7):725–50.

Passaquin AC, Renard M, et al. Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice. Neuromuscul Disord. 2002 Feb;12(2):174–82.

Payne ET, Yasuda N. Nutritional therapy improves function and complements corticosteroid intervention in mdx mice. Muscle Nerve. 2006 Jan;33(1):66–77.

Persky AM, Brazeau GA. Clinical pharmacology of the dietary supplement creatine monohydrate. Pharmacol Rev. 2001 Jun;53(2):161–76.

Pierno S, De Luca A, et al. Chronic administration of taurine to aged rats improves the electrical and contractile properties of skeletal muscle fibers. J Pharmacol Exp Ther. 1998 Sep;286(3):1183–90.

Porter JD, Khanna S, et al. A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum Mol Genet. 2002 Feb 1;11(3):263–72.

Ruegg UT, Nicolas-Metral V, et al. Pharmacological control of cellular calcium handling in dystrophic skeletal muscle. Neuromuscul Disord. 2002 Oct;12 Suppl 1:S155–S161.

Siciliano G, Mancuso M, et al. Coenzyme Q10, exercise lactate and CTG trinucleotide expansion in myotonic dystrophy. Brain Res Bull. 2001 Oct-Nov 1;56(3-4):405–10.

Tarnopolsky MA, Mahoney DJ, et al. Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology. 2004 May 25;62(10):1771–7.

Tedeschi D, Lombardi V, et al. Potential involvement of ubiquinone in myotonic dystrophy pathophysiology: New diagnostic approaches for new rationale therapeutics. Neurol Sci. 2000;21(5 Suppl):S979–S980.

Tidball JG, Wehling-Henricks M. Evolving therapeutic strategies for Duchenne muscular dystrophy: Targeting downstream events. Pediatr Res. 2004 Dec;56(6):831–41.

Tidball JG, Wehling-Henricks M. Damage and inflammation in muscular dystrophy: Potential implications and relationships with autoimmune myositis. Curr Opin Rheumatol. 2005 Nov;17(6):707–13.

Walter MC, Lochmuller H, et al. Creatine monohydrate in muscular dystrophies: A double-blind, placebo-controlled clinical study. Neurology. 2000 May 9;54(9):1848–50.

Walter MC, Reilich P, et al. Creatine monohydrate in myotonic dystrophy: A double-blind, placebo-controlled clinical study. J Neurol. 2002 Dec;249(12):1717–22.

Webb AR, Kline L, et al. Influence of season and latitude on the cutaneous synthesis of vitamin D3: Exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab. 1988 Aug;67(2):373–8.

Yilmaz O, Karaduman A, et al. Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis. Eur J Neurol. 2004 Aug;11(8):541–4.

Zamaria N. Alteration of polyunsaturated fatty acid status and metabolism in health and disease. Reprod Nutr Dev. 2004 May-Jun;44(3):273–82.

Zaveri NT. Green tea and its polyphenolic catechins: Medicinal uses in cancer and noncancer applications. Life Sci. 2006 Mar 27;78(18):2073–80.

These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure or prevent any disease. The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. You should not stop taking any medication without first consulting your physician.